Skip to Content
Søk Menu

Real World Longer-Term Follow-Up Data Confirms the Effectiveness and Safety of Avelumab 1st Line Maintenance Treatment of Low-Burden Urothelial Cancer

Results from the AVENANCE trial suggest that avelumab may provide a promising maintenance treatment option for patients with low-burden urothelial carcinoma, showing encouraging survival and progression-free survival outcomes after chemotherapy.

ASCO GU | Håll dig uppdaterad

Vi publicerar de viktigaste höjdpunkterna från ASCO GU i form av sammanfattningar, onlineartiklar, MEDtalks med internationella och nationella specialister.

Se allt innehåll

Relaterat innehåll

Neeraj Agarwal

Talazoparib and Enzalutamide: A Game-Changer for mCRPC

/ Neeraj Agarwal
ASCOGU25Prostatacancer Play the Video 18:34

Real-World Treatment Patterns of Nivolumab + Cabozantinib Compared with Other 1L IO Combinations in mRCC

/ Cherrishe Brown-Bickerstaff / Jan Andreasen
ASCOGU25Njurcancer
Thomas Powles

Bladder Cancer Treatment Advancements: Key Findings and Progress

/ Thomas Powles
ASCOGU25Blåscancer Play the Video 08:59

Bone Pain as a Key Prognostic Indicator in Castration-Sensitive Prostate Cancer

/ Deniz Tural / Jan Andreasen
ASCOGU25Prostatacancer

Real-Life Data Confirms Avelumab Maintenance Benefits in Metastatic Urothelial Carcinoma

/ Deniz Tural / Jan Andreasen
ASCOGU25Blåscancer

Cabozantinib Real-World Effectiveness in the Second-Line Setting of Metastatic Renal Cell Carcinoma

/ Martin Zarba / Jan Andreasen
ASCOGU25Njurcancer

Danish Study Reveals Doubling of Kidney Cancer Cases and a Growing Gender Gap 

/ Jan Andreasen
ASCOGU25Njurcancer
Petros Grivas

Bladder Cancer: Avelumab Maintenance Shows Benefit for Both Patients With and Without Diabetes Mellitus

/ Petros Grivas
ASCOGU25BlåscancerTyp 2-diabetes Play the Video 02:42
Peter J. Goebell

Real-World Effectiveness of Avelumab in First-Line Maintenance for Bladder Cancer

/ Peter J. Goebell
ASCOGU25Blåscancer Play the Video 06:12
Back to top